Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rose bengal sodium - Provectus Biopharmaceuticals

Drug Profile

Rose bengal sodium - Provectus Biopharmaceuticals

Alternative Names: PH-10; Provecta; PV-10; Rose bengal; Rose bengal disodium; Rose bengal sodium I 125; Rose bengal sodium I 131; Xantryl

Latest Information Update: 11 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Photogen Technologies Inc.
  • Developer Pediatric Oncology Experimental Therapeutics Investigators Consortium; Provectus Biopharmaceuticals
  • Class Antiacnes; Antineoplastics; Antipsoriatics; Antivirals; Benzoates; Fluoresceins; Skin disorder therapies; Small molecules; Xanthenes
  • Mechanism of Action Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants; Interferon modulators; Interleukin 17 modulators; Interleukin-22 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma; Liver cancer; Neuroblastoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Atopic dermatitis; Psoriasis
  • Phase I Liver cancer; Liver metastases; Neuroendocrine tumours
  • Preclinical Cancer
  • Discontinued Acne vulgaris; Breast cancer

Most Recent Events

  • 30 Sep 2019 Provectus Biopharmaceuticals terminates phase III trial in Malignant melanoma (Monotherapy) in USA, Germany, France, Italy and Mexico due to inadequate rate of enrolment (NCT02288897)
  • 15 Jul 2019 Provectus Biopharmaceuticals receives patent allowance for PV 10 in combination with systemic immunomodulatory therapy in USA
  • 03 Jun 2019 Efficacy and adverse events data from a phase I trial in neuroendocrine tumours released by Provectus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top